CEACAM6 and SLC2A1 may also play a role in IPMN tumor progression, with increased expression of these genes in high‐grade versus low‐ and intermediate‐grade IPMNs being previously observed [19, 22, 23, 24]. This evidence concerns the gene SLC2A1 and pancreatic intraductal papillary-mucinous neoplasm.